Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 2
2013 1
2014 3
2015 6
2016 6
2017 4
2018 2
2019 8
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Wallentin L, et al. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717846 Free article. Clinical Trial.
Interleukin-18 in patients with acute coronary syndromes.
Åkerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, Himmelmann A, Katus HA, Storey RF, Wallentin L, Weaver WD, Siegbahn A; PLATO Investigators. Åkerblom A, et al. Clin Cardiol. 2019 Dec;42(12):1202-1209. doi: 10.1002/clc.23274. Epub 2019 Oct 9. Clin Cardiol. 2019. PMID: 31596518 Free PMC article. Clinical Trial.
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HA, Mahaffey KM, Pieper KS, Storey RF, Steg PG, Harrington RA; PLATO Investigators. Wallentin L, et al. Int J Cardiol. 2014 Sep;176(1):300-2. doi: 10.1016/j.ijcard.2014.06.029. Epub 2014 Jun 27. Int J Cardiol. 2014. PMID: 25005338 No abstract available.
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L; PLATO Investigators. Varenhorst C, et al. Eur Heart J. 2015 Aug 1;36(29):1901-12. doi: 10.1093/eurheartj/ehv116. Epub 2015 May 2. Eur Heart J. 2015. PMID: 25935875 Clinical Trial.
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial.
Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L; PLATO Investigators. Ueland T, et al. Atherosclerosis. 2020 Jan;293:35-41. doi: 10.1016/j.atherosclerosis.2019.11.031. Epub 2019 Nov 29. Atherosclerosis. 2020. PMID: 31835039 Clinical Trial.
Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes.
Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L; PLATO Investigators. Ueland T, et al. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):294-302. doi: 10.1161/ATVBAHA.118.311042. Arterioscler Thromb Vasc Biol. 2019. PMID: 30580572 Free article. Clinical Trial.
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L; PLATO Investigators. Lindholm D, et al. Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271. Epub 2016 Dec 8. Clin Chem. 2017. PMID: 27932413 Clinical Trial.
Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome.
Johansson Å, Eriksson N, Lindholm D, Varenhorst C, James S, Syvänen AC, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L; PLATO Investigators. Johansson Å, et al. Hum Mol Genet. 2016 Apr 1;25(7):1447-56. doi: 10.1093/hmg/ddw012. Epub 2016 Jan 21. Hum Mol Genet. 2016. PMID: 26908625 Clinical Trial.
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RD; PLATO Investigators. Åkerblom A, et al. Am Heart J. 2019 Jul;213:57-65. doi: 10.1016/j.ahj.2019.04.006. Epub 2019 Apr 18. Am Heart J. 2019. PMID: 31108273 Clinical Trial.
30 results